Merck Stock Fluctuates Between Patent Concerns and Growth Hopes
This article was created with the help of artificial intelligence.
Key Takeaways
- Merck stock fell 1.36 percent on June 18, 2026, to $113.87 while the overall market gained, reflecting investor concerns about fundamental challenges.
- Keytruda is Merck's highest-revenue drug as a PD-1 inhibitor for cancer treatment, whose approaching patent expiration could trigger sharp revenue and profit decline.
- Positive Phase III trial results from the cooperation with Kelun-Biotech for a Keytruda combination for lung cancer in May 2026 led to gains and demonstrated innovation potential.
- Merck is diversifying its portfolio through multiple therapeutic approaches in oncology and strategic partnerships to close the revenue gap after patent expiration.
- Repeated price declines in a rising market environment show that investors are factoring both macroeconomic pressures and long-term structural issues like the patent cliff into their valuation.
Merck stock (ticker: MRK) declined 1.36 percent on June 18, 2026, closing at $113.87 — at a time when the overall market was rising. The U.S. pharmaceutical giant, not to be confused with German Merck KGaA, faces the strategic challenge of securing its growth momentum beyond the approaching patent expiration of its blockbuster cancer drug Keytruda.
Volatile price movement in Q2 2026
The price movements of recent weeks present a mixed picture. On April 24, 2026, the stock fell 2.37 percent to $111.90, after already declining 1.3 percent to $119.28 on April 7. In both cases, the stock moved against the general market trend, heading downward.
The stock received a positive boost on May 22, 2026, when cooperation partner Kelun-Biotech presented positive results from a Phase III study on combining Keytruda with its own drug for treating lung cancer. The data drove Merck stock higher that day.
Keytruda as the central revenue driver
Keytruda is the highest-revenue drug in Merck's portfolio. The immunotherapy is used to treat various cancer types and belongs to the class of PD-1 inhibitors. These block a mechanism by which cancer cells evade the immune system, enabling a more targeted immune response against tumor cells.
The approaching patent expiration — often called a "patent cliff" — presents Merck with the task of developing new revenue sources in time. A patent cliff describes the sharp revenue and profit decline that occurs when blockbuster drugs lose patent protection and cheaper generics enter the market.
Broader portfolio as a strategic response
Merck is working to avoid relying exclusively on Keytruda. The company is developing additional therapeutic approaches in oncology and expanding its portfolio through partnerships. The collaboration with Kelun-Biotech is an example of this strategy: combination therapies can increase the efficacy of existing drugs and open access to new patient groups.
Analysts are watching how the company's pipeline develops and whether Merck will be able to close the revenue gap that Keytruda's patent expiration will leave. Motley Fool described Merck on June 4, 2026, in an analysis as more than a "one-trick pony" and pointed to the conglomerate's diversification efforts.
Assessment for investors
For investors in the DACH region investing in U.S. pharmaceutical stocks, the volatility of Merck stock means that both short-term pressures from macroeconomic factors and long-term structural issues play a role. The repeated price declines in a rising market environment suggest that investors are factoring fundamental challenges — particularly the patent cliff — into their valuation.
At the same time, positive reactions to study data show that the company has potential to generate new growth momentum through innovation and strategic partnerships. The further development of the pipeline and the ability to bring new products to market maturity will be decisive for how the stock develops in the medium term.